Abstract:The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have marked a new phase of coronavirus disease 2019 (COVID-19). Understanding the recognition mechanisms of potent neutralizing monoclonal antibodies (NAbs) against the spike protein is pivotal for developing new vaccines and antibody drugs. Here, we isolated several monoclonal antibodies (MAbs) against the SARS-CoV-2 spike protein receptor-binding domain (S-RBD) from the B cell receptor repertoires of a SARS-CoV-2 convalescent. Among these MAbs, the antibody nCoV617 demonstrates the most potent neutralizing activity against authentic SARS-CoV-2 infection, as well as prophylactic and therapeutic efficacies against the human angiotensin-converting enzyme 2 (ACE2) transgenic mouse model in vivo . The crystal structure of S-RBD in complex with nCoV617 reveals that nCoV617 mainly binds to the back of the "ridge" of RBD and shares limited binding residues with ACE2. Under the background of the S-trimer model, it potentially binds to both "up" and "down" conformations of S-RBD. In vitro mutagenesis assays show that mutant residues found in the emerging new lineage B.1.1.7 of SARS-CoV-2 do not affect nCoV617 binding to the S-RBD. These results provide a new human-sourced neutralizing antibody against the S-RBD and assist vaccine development. IMPORTANCE COVID-19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic has posed a serious threat to global health and the economy, so it is necessary to find safe and effective antibody drugs and treatments. The receptor-binding domain (RBD) in the SARS-CoV-2 spike protein is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor. It contains a variety of dominant neutralizing epitopes and is an important antigen for the development of new coronavirus antibodies. The significance of our research lies in the determination of new epitopes, the discovery of antibodies against RBD, and the evaluation of the antibodies' neutralizing effect. The identified antibodies here may be drug candidates for the development of clinical interventions for SARS-CoV-2.

Structural basis of a shared antibody response to SARS-CoV-2

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

Diverse Immunoglobulin Gene Usage and Convergent Epitope Targeting in Neutralizing Antibody Responses to SARS-CoV-2

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

Structural basis of SARS-Cov-2 spike recognition by engineered synthetic multivalent VHH antibodies

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection

Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

Potent and Protective IGHV3-53/3-66 Public Antibodies and Their Shared Escape Mutant on the Spike of SARS-CoV-2.

Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-2